As of Feb 24
| +0.03 / +0.08%|
The 6 analysts offering 12-month price forecasts for Haemonetics Corp have a median target of 40.00, with a high estimate of 42.00 and a low estimate of 34.00. The median estimate represents a +6.58% increase from the last price of 37.53.
The current consensus among 10 polled investment analysts is to Hold stock in Haemonetics Corp. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.